Lilly is championing

Transparency

Our experience has taught us that transparency in our operations can help to build trust with stakeholders. Transparency can also guard against corruption and unethical business practices. By listening and responding openly to our stakeholders’ concerns, we can improve our transparency and the way we do business.


Consistent with Lilly’s policy of open disclosure, we became the first pharmaceutical company to voluntarily launch an online clinical trial registry. Since 2002, Lilly has registered all Lilly-sponsored Phase II, Phase III and Phase IV clinical studies, conducted anywhere in the world that were initiated on or after October 15, 2002, on www.clinicaltrials.gov. Additionally, Lilly began registering all Phase I clinical studies commencing on or after October 1, 2010.


In addition, we believe that transparency of business practices that involve financial payments, or other forms of value, to physicians is essential for building trust. As a result, we have taken a number of steps to provide information on important aspects of how we interact with key partners in the pursuit of advancements in medicine.

From 1 October 2015, all member companies of Medicines Australia are required to report information relating to any health care professional who receives payment for consulting or speaker services and any support to attend educational events.  Click the relevent file below to download.

1 Oct 2015 to 30 Apr 2016 (PDF)  or 1 Oct 2015 to 30 Apr 2016 (CSV) 

1 May 2016 to 31 Oct 2016 (PDF) or 1 May 2016 to 31 Oct 2016 (CSV) 

1 Nov 2016 to 30 Apr 2017 (PDF) or 1 Nov 2016 to 30 Apr 2017 (CSV) 

1 May 2017 to 31 Oct 2017 (PDF) or 1 May 2017 to 31 Oct 2017(CSV)

1 Nov 2017 to 30 April 2018 (PDF) or 1  Nov 2017 to 30  April 2018 (CSV)